MetaCap

BioNTech (BNTX) vs Neurocrine Biosciences (NBIX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neurocrine Biosciences (NBIX) has outperformed BioNTech (BNTX) over the past year, gaining 6.2% versus a loss of 15.3%. Over five years, NBIX leads with a +73.1% price change compared with -76.7% for BNTX. BioNTech is the larger company by market cap ($20.07 billion vs $15.24 billion), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTX-15.30%NBIX+6.16%
+33%+8%-18%
Nov 21, 20251 yearNov 20, 2026
BNTX-72.06%NBIX+75.04%
+115%+17%-81%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTX versus NBIX key metrics
MetricBNTXNBIX
Share price$80.96$150.57
Market cap$20.07B$15.24B
1-day change-0.52%-3.84%
YTD return-14.96%+6.16%
1-year return-15.30%+6.16%
5-year return-76.74%+73.11%
P/E ratio (TTM)—22.34
Forward P/E—12.24
EPS (TTM)$-6.83$6.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.86B
Revenue growth (YoY)—+21.45%
Net income (latest FY)—$478.60M
Gross margin—98.18%
Operating margin—21.64%
Net margin—16.73%
52-week high$124.00$186.12
52-week low$79.52$122.14
Distance from 52-week high-34.71%-19.10%
Analyst consensusbuystrong_buy
Avg. price target upside+38.51%+38.50%
Average volume1.08M1.34M
Shares outstanding247.93M101.22M
Employees7,8072,500
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NBIX has outperformed BNTX by 21.5 percentage points over the past year.

About BioNTech

BNTX stock →

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees

About Neurocrine Biosciences

NBIX stock →

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees

BNTX vs NBIX FAQ

Which is bigger, BioNTech or Neurocrine Biosciences?

BioNTech (BNTX) is larger, with a market capitalization of $20.07B compared with $15.24B for Neurocrine Biosciences (NBIX).

Which stock has performed better over the past year, BNTX or NBIX?

NBIX returned +6.16% over the past 12 months, compared with -15.30% for BNTX (price return, excluding dividends). Past performance does not predict future results.

Are BioNTech and Neurocrine Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons